Ascension Medical Biotechnology Primed EVs for Bone, Dental Defects
Summary
Ascension Medical Biotechnology Co., Ltd. has filed US Patent Application US20260108559A1 with the USPTO, published on 23 April 2026 (filed 23 October 2025). The application covers primed extracellular vesicle compositions comprising upregulated miRNA and a biologically or pharmaceutically acceptable carrier, alongside methods of producing the compositions via stem cell cultivation with Polygonum multiflorum Thunb extract, baicalin, and bone morphogenetic protein 6. Claims encompass therapeutic use for preventing, treating, or ameliorating bone defects and dental defects in subjects in need thereof.
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108559A1, assigned to Ascension Medical Biotechnology Co., Ltd., covering compositions of primed extracellular vesicles and methods of use for bone and dental defects. The compositions comprise primed extracellular vesicles with upregulated miRNA where fold change versus naturally occurring EVs exceeds 1, combined with a biologically or pharmaceutical acceptable carrier. Production methods involve cultivating stem cells in media containing Polygonum multiflorum Thunb extract, baicalin, and/or bone morphogenetic protein 6.
Biotechnology and pharmaceutical companies engaged in regenerative medicine, cell therapy, or extracellular vesicle-based product development should review the published claims to assess freedom-to-operate considerations, licensing opportunities, or differentiation strategies for competing R&D programmes in bone regeneration and dental defect treatments.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS OF EXTRACELLULAR VESICLES AND METHOD USING THE SAME
Application US20260108559A1 Kind: A1 Apr 23, 2026
Assignee
Ascension Medical Biotechnology Co., Ltd.
Inventors
Ju-Sheng Shieh, Yu-Tang Chin
Abstract
The present disclosure provides a composition comprising primed extracellular vesicles and a biologically or pharmaceutically acceptable carrier, wherein the primed extracellular vesicles comprise an upregulated miRNA, and a fold change of the upregulated miRNA of the primed extracellular vesicles compared to miRNA of naturally occurring extracellular vesicles is greater than 1. The present disclosure further provides a method for preventing, treating, or ameliorating a bone defect or a dental defect comprising administering the composition of the present disclosure to a subject in need thereof. The present disclosure also provides a method for producing the composition. The method comprises cultivating a stem cell in a culture medium containing a Polygonum multiflorum Thunb extract and at least one selected from the group consisting of baicalin and bone morphogenetic protein 6 to obtain a cell culture.
CPC Classifications
A61K 35/28 A61K 31/7105 A61L 27/365 A61L 27/3834 C12N 5/0668 A61L 2430/02 B82Y 5/00 C12N 2500/30 C12N 2501/155
Filing Date
2025-10-23
Application No.
19366546
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.